Fianlimab

DB18858InvestigationalProtein Based Therapies

Fianlimab is under investigation in clinical trial NCT06190951 (A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-pd1 Alone in Adult Participants With Resectable Stage...

Mechanism: Pharmacologically active on Lymphocyte activation gene 3 protein
Curator reviewed
Also known as: Anti-lag-3 monoclonal antibody regn3767
Code names: R3767 · REGN-3767

Resolves to

Compound

UNIIOX5LRQ5H6KCAS2126132-98-5

Targets

P18627LAG3

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

42Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Fianlimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account